BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 132 filers reported holding BRIDGEBIO PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,676,705 | +164.4% | 1,277,084 | +72.5% | 0.09% | +184.4% |
| Q2 2023 | $12,734,725 | -1.5% | 740,391 | -5.0% | 0.03% | -13.5% |
| Q1 2023 | $12,924,773 | +160.5% | 779,540 | +19.7% | 0.04% | +131.2% |
| Q4 2022 | $4,962,228 | -42.7% | 651,211 | -25.3% | 0.02% | -44.8% |
| Q3 2022 | $8,660,000 | +530.7% | 871,207 | +476.0% | 0.03% | +480.0% |
| Q2 2022 | $1,373,000 | -73.5% | 151,263 | -70.3% | 0.01% | -66.7% |
| Q1 2022 | $5,172,000 | -48.8% | 509,548 | -15.9% | 0.02% | -31.8% |
| Q4 2021 | $10,111,000 | +361.7% | 606,189 | +1197.4% | 0.02% | +340.0% |
| Q3 2021 | $2,190,000 | +129.1% | 46,722 | +198.0% | 0.01% | +150.0% |
| Q2 2021 | $956,000 | -96.8% | 15,679 | -96.8% | 0.00% | -97.4% |
| Q1 2021 | $29,804,000 | +154.6% | 483,828 | +194.0% | 0.08% | +129.4% |
| Q4 2020 | $11,704,000 | +136.0% | 164,589 | +24.5% | 0.03% | +88.9% |
| Q3 2020 | $4,959,000 | – | 132,175 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 3,835,722 | $103,449,000 | 44.18% |
| Kohlberg Kravis Roberts & Co. L.P. | 36,900,661 | $995,211,000 | 12.26% |
| SC US (TTGP), LTD. | 2,544,738 | $68,632,000 | 4.69% |
| Cormorant Asset Management, LP | 2,780,885 | $75,000,000 | 4.31% |
| Perceptive Advisors | 6,706,268 | $180,868,000 | 4.15% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $717,968,000 | 3.22% |
| Hillhouse Capital Management | 2,035,790 | $54,905,000 | 1.75% |
| Alpine Group USVI, LLC | 20,000 | $539,000 | 1.70% |
| HHLR ADVISORS, LTD. | 2,352,900 | $63,458,000 | 1.42% |
| SCGE MANAGEMENT, L.P. | 588,235 | $15,865,000 | 0.79% |